Two cases of Bacillus cereus meningitis in immunocompromised children at our hospital within a 2-month period prompted us to review B. cereus-related invasive disease. We identified 12 patients with B. cereus isolated in blood cultures from September 1988 through August 2000 at our institution. Three of these patients also had B. cereus isolated from CSF specimens; 1 additional patient had possible CNS involvement (33%, group A), whereas 8 patients had no evidence of CNS involvement (67%, group B). Patients in group A were more likely to have neutropenia at the onset of sepsis and were more likely to have an unfavorable outcome. They were also more likely to have received intrathecal chemotherapy in the week before the onset of their illness. Two patients from group A died. One survived with severe sequelae. The fourth patient had mild sequelae at follow-up. No sequelae or deaths occurred among patients in group B. In patients with unfavorable outcomes, the interval from the time of recognition of illness to irreversible damage or death was short, which demonstrates a need for increased awareness, early diagnosis, and more-effective therapy, particularly that which addresses B. cereus toxins.
pressed patients, injection drug users, neonates, and patients with intraventricular shunts [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
During the summer of 1999, meningitis due to B. cereus occurred in 2 patients with leukemia at St. Jude Children's Research Hospital, Memphis. A review of the literature revealed only 6 previously reported cases of B. cereus involving the CNS in patients with leukemia [5] [6] [7] [8] [10] [11] [12] . Of these, only one patient survived [8] . Against this backdrop of relatively rare but consequential episodes of B. cereus infection in immunosuppressed patients and with little information regarding infection in children, we did a retrospective review of the clinical and epidemiological features of B. cereus infection in the immunocompromised patients at our hospital.
MATERIALS AND METHODS
Microbiology records from September 1988 through August 2000 were reviewed, and all patients with isolation of B. cereus from a normally sterile body site were identified. Charts of identified patients in the study period then were reviewed for clinical and epidemiological information, including demographic characteristics, details of the B. cereus isolates, and type and disposition of the central venous catheter. We also noted the clinical signs and symptoms at the time of presentation, treatment methods, and outcome. In addition, antibiotic use, steroid use, procedures (including lumbar puncture), and dietary history (recent consumption of rice and use of enteral nutrition) during the month before the episode were recorded. Quantitative blood cultures were done on clinical blood samples by use of ISO-LATOR 1.5 Microbial Tubes (Wampole).
Catheter-related infection was defined as culture-proven bacteremia in which the colony count from the blood culture obtained via the catheter was у5 times the colony count of the peripheral blood culture, with both samples being drawn within 30 min and not separated by intervening antimicrobial administration [14] . Those episodes-which either lacked paired specimens from the catheter and a peripheral venipuncture or in which a dose of antibiotic was administered between the time the 2 cultures were drawn-were labeled as indeterminate.
Identification of B. cereus was made on the basis of Gram stain, colony morphology, and hemolysis on blood agar and analysis with the BBL CRYSTAL gram-positive identification panel (Becton Dickinson). Before December 1997, isolates were identified by use of the Minitek procedure (Becton Dickinson) and biochemical characteristics [15] .
Selected isolates were ribotyped by use of the RiboPrinter Microbial Characterization System (Qualicon) [16] . These included paired blood and CSF isolates from both patients with documented meningitis.
Statistical tests included Fisher's exact test and the Cochran Mantel-Haenszel test. Analyses were done by use of SAS software (SAS Institute).
RESULTS
Twelve patients with B. cereus isolated in blood cultures were identified during September 1988-August 2000 (figure 1). Two of the patients (patients 4 and 6) were previously reported from our institute by other investigators who were studying the intravascular hemolysis associated with B. cereus septicemia [17] . The median age of the patients was 11.5 years (range, 4-24 years). Seven patients were male. Eight patients were white and 4 were black. Other details of the patients are shown in table 1.
After reviewing clinical information, the patients were stratified into 2 distinct groups: group A was composed of patients who had documented or suspected CNS involvement, and group B was composed of patients who showed no evidence of CNS infection.
All patients in group A had leukemia; 3 of the 4 were undergoing therapy for relapse. Only 1 of 8 patients in group B had leukemia. Details of group A patients are shown in table 2. Two patients (patients 10 and 12) had antemortem cultures of CSF samples that yielded B. cereus. The Gram stain of their centrifuged CSF samples showed numerous gram-positive rods that exhibited the phenomena of filamentation, particularly in patient 10 (figure 2). It is of note that, in this patient, the CSF vancomycin level was 2.2 mg/mL (CSF obtained 9 h after the last dose of vancomycin, which was dosed at 15 mg/kg per dose every 8 h). Serum creatinine at that time was 0.7 mg/dL, The finding of multiple cerebral hypodense lesions in close proximity to the subarachnoid space in the clinical context of B. cereus septicemia was suggestive of septic emboli, but this finding also could have been due to sterile emboli or hypoperfusion injury. Lumbar puncture was not done initially because of the unstable condition of the patient; however, a CSF examination done 2 weeks later yielded abnormal findings, with increased protein seen. Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and abdominal pain, were present in all 4 patients in group A. Four patients in group B also had gastrointestinal symptoms. Two patients (patients 4 and 12) from group A died. One survived with severe sequelae (patient 10). The fourth patient had mild sequelae at follow-up. No sequelae or deaths occurred among patients in group B. Other clinical findings from the 2 groups are compared in table 3. Patients in group A were more likely to have received corticosteroids or cephalosporins within the previous 30 days, to have been hospitalized in the preceding week, to have neutropenia, and to have received induction therapy than were patients in group B. All patients in group A had a lumbar puncture with intrathecal instillation of the chemotherapy (methotrexate, hydrocortisone, and cytarabine) during the week before the event. In contrast, no patient in group B had undergone a lumbar puncture within 4 weeks before onset of B. cereus infection. All 12 patients had a central venous catheter inserted. Nine of them had the catheter removed as part of disease management. Six of the removed catheters were sent for culture, 3 of which tested positive for B. cereus. Five patients had other organisms as coisolates from initial blood cultures. Only 1 patient's infection (patient 11) met our definition of catheter-related infection. The remainder of the patients were unassessable because quantitative central line and peripheral blood cultures were not collected or because a dose of antibiotic was administered between the drawing of the 2 cultures, obscuring the role of the catheter as a focus of infection [14] .
Ribotyping of paired blood and CSF isolates for the most recent patients (patients 10 and 12) showed concordance between isolates of the same patient. Of the 8 isolates from 6 patients, 5 distinct ribotype patterns were identified, which indicates that the corresponding infections were not caused by closely related strains. Two patients (patients 6 and 12), who presented 16 months apart with no apparent epidemiological links, had isolates with similar ribotypes. Additional analysis associated with the ribotyping study indicated that one isolate (that of patient 4) was Bacillus thuringiensis, rather than B. cereus, as indicated by means of routine microbiological methods. We retained this patient in our series because the patient met the inclusion criteria on the basis of routine microbiological tests.
DISCUSSION
There have been several case reports of B. cereus infections in immunocompromised hosts, mainly in adults [5] [6] [7] [8] [9] [10] [11] [12] [13] [18] [19] [20] [21] . These reports included only a few patients with CNS involvement, most of whom died. In our series of B. cereus infections, patients were categorized according to the presence or absence of CNS involvement. In our cohort of 4 patients with CNS involvement (group A), patients were more likely to have had neutropenia, to have received induction therapy or to have been in relapse, to have received systemic steroids, to have been recently hospitalized, to have been recently treated with cephalosporins, and to have been diagnosed with leukemia (table 3) . These associated factors suggest that the patients with CNS involvement were more immunosuppressed than were those who did not develop CNS complications. Therefore, the poor outcome among patients in group A may have been an indirect consequence of the greater immunosuppression of the patients in this group, rather than due entirely to the spread of the organism to the CNS.
It is of interest that all 4 patients in group A underwent a lumbar puncture with intrathecal methotrexate, hydrocortisone, and cytarabine in the week before onset of infection, compared with 0 of 8 patients in group B. This association may simply be because patients in induction therapy are predisposed to fulminant infection, including CNS spread, and because they may incidentally receive frequent intrathecal treatments. Other explanations include contamination during the lumbar puncture procedure, secondary CNS spread induced by lumbar puncture during bacteremia-as has been observed in animal models, but not in immunocompromised humans [22, 23] -or chemotherapy-induced changes in the blood-brain barrier. We do not favor the hypothesis that the organism spread to the CSF at the time of the lumbar puncture procedure because there were no clinical signs or symptoms suggesting that the patients had bacteremia at that time. We do, however, suspect that recent intrathecal chemotherapy may be related to the development of meningitis. Intrathecal methotrexate is occasionally associated with aseptic meningitis, which is indicative of chemical arachnoiditis [24, 25] . On a similar note, intrathecal cytarabine has been reported to cause myelopathy and occasional aseptic meningitis [26, 27] . Although there are few data on the effect of intrathecal chemotherapy on the blood-brain barrier, we speculate that chemotherapy-induced changes in the integrity of the blood-brain barrier may predispose the patient to the meningeal spread of organisms when bacteremia occurs during the interval after the lumbar puncture. Eight of the 12 patients had gastrointestinal signs or symptoms at the time of presentation, which suggests that the gastrointestinal tract was a source of infection. Other investigators have speculated that the presence of abdominal symptoms may be a factor that differentiates patients with a fulminant septicemic course from patients with a more benign course [11] . We did not observe this relationship in our series of patients. However, 3 of the 4 patients in group A versus 0 of 8 in group B had B. cereus in cultures of their stool or rectal swab samples obtained within 72 h of presentation. It is not clear if this colonization was the source of or the result of the bacteremia.
Another possible source of the bacteremia is the central venous catheter. Although B. cereus was cultured in 3 instances from the patients' catheter tips, this cannot be considered to be definitive evidence of catheter-related infection in the setting of bacteremia that may have come from another source. On the basis of our rigorous definition of catheter-related infection, there was only 1 proven case. However, the possibility of catheter-related infection was not excluded for the other patients. Regardless of this uncertainty, the catheter always was considered as a possible source of infection, and catheter removal was routinely part of the clinical treatment of these patients.
On the basis of an epidemiological investigation and analysis of isolates with pulsed-field gel electrophoresis, a previous study of 3 oncology patients with B. cereus bacteremia or septicemia who presented over a course of 10 days found no evidence of a common source [28] . Similarly, by use of an automated ribotyping system for epidemiological typing of 8 clinical isolates from 6 of the patients, we found no evidence to suggest a common environmental source for these infections.
Previous studies have shown that variances in toxin production between isolates of B. cereus are correlated with differences in the clinical courses of the associated infections [29, 30] . Among the toxins produced by B. cereus is cereolysin, an oxygen labile exotoxin that is a member of a well-characterized family of hemolysins found in gram-positive bacteria [31] . Other toxins include enterotoxin, emetic toxin, phospholipase C, and other hemolysins, such as sphingomyelinase. Patients 4 and 6 had intravascular hemolysis [17] , and patients 10 and 12 had evidence of hemolysis in the CSF. Given the possible role of exotoxins in the severe tissue damage that is typical of infections with B. cereus, the rapid progression of the infection, and the apparent inability of antibiotics alone to halt the disease process, alternative forms of intervention warrant consideration. As reported elsewhere, exchange transfusion was used in the management of intravascular hemolysis in patient 6 [17] . Likewise, the role of CSF exchange, reported elsewhere to be useful in the management of intrathecal drug overdose, needs NOTE. ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; AMML, acute myelomonocytic leukemia; ANC, absolute neutrophil count; MDS, myelodysplastic syndrome; SAH, subarachnoid hemorrhage. Patients described in Yoshida et al. [9] and Musa et al. [13] , as well as patient 6 in this series, were strongly suspicious for CNS involvement with B. cereus but did not have confirmatory microbiologic or pathologic evidence.
a Total WBC count.
to be explored as a method of reducing CSF toxin load [32, 33] . The use of iv immunoglobulin also may be useful for these patients; however, the presence of neutralizing antibody for toxins produced by this organism has not been confirmed. When comparing the patients with meningitis in this series to those reported in the literature, certain similarities are apparent (table 4). All the patients had neutropenia, were in an intensive phase of chemotherapy, and had unfavorable outcome, despite receiving appropriate antibiotic therapy in most cases [5] [6] [7] [8] [9] [10] [11] [12] [13] . It is of note that 5 patients, including 2 of the patients in this series, had subarachnoid hemorrhage [7, [9] [10] [11] . The one survivor before this report was a 3-year-old child with acute lymphocytic leukemia who had neutropenia at the time of admission, but not at the time of CNS deterioration [8] . The resolution of neutropenia may have played a key part in localization of the infection in the form of abscesses and a relatively favorable outcome.
In summary, we reiterate that B. cereus isolated from clinical material from a sterile body site, especially from an immunosuppressed host, should not be disregarded as a contaminant. Risk factors favoring a fulminant course and poor outcome of B. cereus bacteremia include an underlying diagnosis of leukemia, being in relapse or in the induction phase of chemotherapy, the presence of neutropenia, receiving systemic corticosteroids or third-generation cephalosporins, recent hospitalization, and undergoing a recent lumbar puncture procedure with intrathecal chemotherapy. Clinicians should be attentive to these risk factors. We also note that ceftazidime monotherapy, which is used frequently as empiric therapy for patients with neutropenia who have unexplained fever, would be unlikely to eradicate B. cereus bacteremia and its sequelae. Therefore, use of alternative antibiotic regimens, such as vancomycin plus a carbapenem in patients with associated gastrointestinal symptoms or in those with a preliminary report of gram-positive bacilli in blood cultures, should be considered. There continues to be a poor outcome among immunosuppressed patients with meningitis due to B. cereus, with a short interval between onset and irreversible injury, which emphasizes the need to explore new methods for early diagnosis and more-effective therapy, including measures that address the role of toxins.
